

Commissioner For Patents, Box PCT, United States Patent and Trademark Office, Washington, D.C. 20231, www.uspto.gov

U.S. APPLICATION NUMBER NO	FIRST NAMED APPLICANT	ATTY. DOCKET NO
09/701,947	Elliot Altman	235.00010101
INTERNATIONAL APPLICATION NO		
PCT/US99/23731		
IA FILING DATE	PRIORITY DATE	
10/12/1999	10/13/1998	

Victoria A Sandberg
Mueting Raasch & Gebhardt
P O Box 581415
Minneapolis, MN 55458

CONFIRMATION NO. 9854

371 FORMALITIES LETTER



OC00000006883168

Date Mailed: 10/10/2001

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fees
- Indication of Small Entity Status
- Priority Document
- Biochemical Sequence Diskette
- Biochemical Sequence Listing
- Claims
- Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Drawings
- Information Disclosure Statements
- Initial Application Filing Fees
- Oath or Declaration
- Oath or Declaration
- Original Specification
- Request for Immediate Examination
- Small Entity Statement
- Small Entity Statement

Seq. List Due 12/10/01
Seq. List Stat 4/10/02

RECEIVED

OCT 15 2001

MUETING & RAASCH

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with

the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
- **APPLICANT MUST PROVIDE:**
 - An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
 - For Rules Interpretation, call (703) 308-4216
 - To Purchase PatentIn Software, call (703) 306-2600
 - For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTH FROM THE DATE OF THIS NOTICE OR BY 22 or 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

CHRISTINE S WASHINGTON

Christine S. Washington
Telephone: (703) 305-3752

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
09/701,947	PCT/US99/23731	235.00010101

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Elliot Altman Group Art Unit: 1642

Serial No.: 09/701,947 Examiner: Unknown

Confirmation No.: 9854 Docket No.: 235.0001 0101

Filed: December 5, 2000

Title: STABILIZED BIOACTIVE PEPTIDES AND METHODS OF IDENTIFICATION, SYNTHESIS AND USE

Assistant Commissioner for Patents
Attn: Box PCT
Washington, D.C. 20231

We are transmitting the following documents along with this Transmittal Sheet (which is submitted in triplicate):

Small entity status is entitled to be asserted in the above-identified application.

An itemized return postcard.

A Petition for Extension of Time for 1 month(s) and a check in the amount of \$ 55.00 for the required fee.

An Information Disclosure Statement (pgs); copies of applications; 1449 forms (pgs); and copies of documents cited on the 1449 forms.

Other: Copy of Notification of Missing Requirements Under 35 U.S.C. 371 in the U.S. Designated/Elected Office (2 pgs.); Communication Requesting Entry of Sequence Listing (2 pgs.); paper form of SEQUENCE LISTING (36 pgs); Computer Form of SEQUENCE LISTING (1 diskette)

Amendment No Additional fee is required. The fee has been calculated as shown:

Fee Calculation for Claims Pending After Amendment					
	Pending Claims after Amendment (1)	Claims Paid for Earlier (2)	Number of Additional Claims (1-2)	Cost per Additional Claim	Additional Fees Required
Total Claims				x \$9 =	
Independent Claims				x \$42 =	
One or More New Multiple Dependent Claims Presented? If Yes, Add \$140 Here →					
Total Additional Claim Fees Required					

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers and please charge any additional fees or credit overpayment to Deposit Account No. 13-4895. Triplicate copies of this sheet are enclosed.

MUETING, RAASCH & GEBHARDT, P.A.

Customer Number: 26813

By: 

Name: David L. Provence

Reg. No.: 43,022


Direct Dial: 612-305-1005

Facsimile: 612-305-1228

CERTIFICATE UNDER 37 CFR §1.10:

"Express Mail" mailing label number: EL888272776US Date of Deposit: January 16, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR §1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Attn: Box PCT, Washington, D.C. 20231.

By: 
Name: Carol L. Altman

SMALL ENTITY TRANSMITTAL UNDER RULE 110